(Total Views: 117)
Posted On: 06/10/2021 1:31:36 PM
Post# of 43998
$IKT Inhibikase Therapeutics, Inc. - The CEO is making an important presentation today on the company's leading role in monoclonal antibody treatments for infectious diseases including the emerging Covid-19 Variants.
LD Micro Virtual Invitational XI
Date: Thursday, June 10, 2021
Time: 11:30am ET
Dr. Werner will present and discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the Company's lead asset being developed for the treatment of Parkinson's disease in the brain and gastrointestinal tract.
Webcasts of the presentations will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website, www.inhibikase.com. An archived replay of the webcasts will be available for approximately 30 days following each event.
LD Micro Virtual Invitational XI
Date: Thursday, June 10, 2021
Time: 11:30am ET
Dr. Werner will present and discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the Company's lead asset being developed for the treatment of Parkinson's disease in the brain and gastrointestinal tract.
Webcasts of the presentations will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website, www.inhibikase.com. An archived replay of the webcasts will be available for approximately 30 days following each event.
(0)
(0)
